Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Robust CD8 T-cell response generated via attenuated Plasmodium sporozoite prime and multi-epitope mRNA vaccine boost.

Created on 18 Nov 2026

Authors

Sahaana Arumugam, Mariah Hassert, Blandine Franke-Fayard, John T Harty

Published in

Journal of immunology (Baltimore, Md. : 1950). Volume 215. Issue 11. Nov 02, 2026.

Abstract

Plasmodium infections and subsequent malaria disease remain a global health scourge. Liver-resident and circulating memory CD8 T cells elicited by whole parasite vaccines such as genetically or radiation-attenuated sporozoites can provide potent immunity to Plasmodium infection and prevent the development of the symptomatic blood stage of infection in humans, nonhuman primates, and mice. However, this requires multiple, large doses of attenuated sporozoites, posing numerous logistical challenges. To partially address these logistical challenges, here, we prime CB6F1 mice with a human weight-normalized, subprotective single dose of genetically or radiation-attenuated Plasmodium berghei sporozoites to elicit liver-resident and circulating memory T cells prior to boosting with a novel lipid nanoparticle mRNA vaccine encoding multiple CD8 T-cell epitopes from liver-stage proteins. We show that boosting primed mice with this mRNA vaccine engenders sterilizing immunity against sporozoite challenge by generating a robust liver-stage-specific CD8 T-cell response when administered intravascularly or intramuscularly. Thus, combining a single, dose-sparing attenuated sporozoite immunization with a multi-epitope translationally relevant mRNA vaccine can engender protective immunity against P. berghei sporozoite challenge via the generation of a potent circulating and resident memory liver CD8 T-cell response. Minimizing the number of attenuated sporozoite doses required to prime CD8 T cells with a full complement of liver-stage malaria-specific epitopes effectively mitigates some logistical challenges associated with attenuated sporozoite vaccination.

PMID:
43043975
Bibliographic data and abstract were imported from PubMed on 18 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 0
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement